同时的PIK3CA突变通过EGFR突变肺癌的炎症信号促进缓解症
Meiting Yue1,2,3, Zhen Qin4, Shijie Tang5
1Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
在EGFR突变肺癌中同时发生的PIK3CA突变会导致缓冲症,促进疾病的进展. 这种由NF-κB介导的缓冲症可以用阿司匹林治疗,这提供了一个新的临床策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- PIK3CA突变经常与癌症驱动因素 (如肺癌中的EGFR) 并存.
- 卡切西亚是一种复杂的系统性疾病,与瘤与器官相互作用和癌症死亡率有关.
研究的目的:
- 研究PIK3CA同步突变在EGFR突变肺癌中的作用.
- 了解由PIK3CA突变驱动缓冲症和恶性进展的机制.
- 为了评估PIK3CA驱动的缓解症的治疗策略.
主要方法:
- 基因工程小鼠模型 (GEMMs) 和临床数据的综合分析.
- 评估对治疗的反应中缓解症的发展和瘤进展.
- 研究分子通路,包括NF-κB激活.
主要成果:
- 同时发生的PIK3CA突变在EGFR突变肺癌中优先驱动缓冲症,促进进展.
- 奥西默提尼布 (Osi) 在敏感模型中有效治疗PIK3CA突变介导的缓解症.
- 化疗未能改善Osi耐药模型中的缓解症,尽管抑制了瘤.
- 由PIK3CA驱动的缓解症涉及NF-κB的激活,可以通过阿司匹林减轻.
结论:
- 在EGFR突变肺癌中,PIK3CA突变在促进缓冲症而不是启动癌症方面发挥着独特的作用.
- 联合阿司匹林治疗显示出管理PIK3CA驱动的缓解症的潜力,特别是在Osi抗性病例中.
- 这项研究为PIK3CA的功能提供了洞察力,并为患有空心的肺癌患者提出了新的治疗方法.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle
Abnormal Proliferation
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
